Pantoprazole, amoxycillin and either azithromycin or clarithromycin for eradication of <i>Helicobacter pylori</i> in duodenal ulcer

Včev, Aleksandar; Štimac, Davor; Ivandić, Ante; Včeva, Andrijana; Takač, Boris; Pezerović, Davorin

doi:10.1046/j.1365-2036.2000.00662.x

Cited by 17 publications

(11 citation statements)

References 14 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the shorter half-life of clarithromycin may increase the dissemination of H. pylori-resistant organisms into the community (31). There is also a possibility that H. pylori has nutritional effects (32).…”

Section: Discussionmentioning

confidence: 99%

Comparison of Azithromycin and Clarithromycin Triple Therapy Regimens for Helicobacter Pylori Eradication in hemodialysis Patients

et al. 2012

View full text Add to dashboard Cite

BackgroundHelicobacter pylori eradication with clarithromycin is more expensive than with azithromycin.ObjectivesThis study aimed to compare the effectiveness of these two antibiotics in eradicating H. pylori in hemodialysis (HD) patients.Patients and MethodsThis is a prospective, randomized, double-blinded clinical trial analysis of HD patients. Patients who had dyspepsia and showed positive results for two of three tests, anti-H. pylori serology, H. pylori stool antigen (HpSAg), or Urease Breath Test (UBT), were included in the study. The subjects consisted of 39 dialysis patients who were randomly divided into two groups that received medication twice daily. Group OAC received 20 mg omeprazol, 500 mg amoxycilin, and 250 mg clarithromycin, and Group OAAz received 20 mg omeprazol, 500 mg amoxicillin, and 250 mg azithromycin. Both regimens were administered for 14 days. Eradication was investigated by performing the UBT and the HpSAg test eight weeks later.ResultsThis study began with 39 patients, 37 of which completed the treatment schedule (20 males and 17 females, mean age 59 years). Two patients died due to MI before beginning treatment. In the OAC group, negative results on the UBT and HpSAg tests were found in 82.4% and 88.2% of the participants, respectively. In the OAAz group, these values were 80% and 85%, respectively. The data showed that the difference between the two regimens was not significant (P = 1.0).ConclusionsAccording to the data, no differences in eradication rates were apparent between the azitromycin and the claritromycin regimens. However, lower cost and fewer complaints could be considered as an advantage of the triple therapy with azithromycin.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of Azithromycin and Clarithromycin Triple Therapy Regimens for Helicobacter Pylori Eradication in hemodialysis Patients

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Using this fundamental theory, many antiulcer drugs have been developed over the past few decades that provide gastro-protective effects and/or anti-secretory effects. Among these agents, strong anti-secretory compounds, such as histamine H 2 -receptor antagonists and proton-potassium ATPase inhibitors have dramatically increased therapeutic efficacy so that 90-95% of the individuals suffering from peptic ulcer disease can be healed [194]. Unfortunately, the high ratio of recurrence of peptic ulcer disease following the end of treatment with such anti-secretory agents remains problematic.…”

Section: New Therapeutic Approachesmentioning

confidence: 97%

Helicobacter pylori Current Chemotherapy and New Targets for Drug Design

Williamson¹

2001

CPD

View full text Add to dashboard Cite

Helicobacter pylori infection is a major cause of many diseases of the gastrointestinal tract, including gastritis, non-ulcer dyspepsia, peptic ulcer disease, and gastric cancers. It is estimated that more than half of the human race is affected by this organism. Although effective treatments are available which will eliminate the organism in about 90 percent; of cases in developed countries, the pandemic occurrence of Helicobacter pylori infection coupled with its ability to develop resistance to our current arsenal of antimicrobial regimens and subsequently reinfect patients makes the pathogenic potential of this microorganism a major global health concern. Provided is a review of the current and evolving therapeutic regimens used in the eradication of Helicobacter pylori, the difficulties associated with in vitro drug screening, as well as potentially new therapeutic targets. In addition, the discovery, the unique physiology, biochemistry, and pathogenicity of this remarkable microorganism is examined.

show abstract

“…In a Russian study, a seven day course of triple therapy with only three days coverage of azithromycin 1000 mg once daily resulted in 72% ITT eradication (21). In a randomized control trial in which pan-toprazole, amoxicillin, and either clarithromycin or azithromycin were administered for seven days, eradication rates were 81% and 78% respectively and both regimens were considered to be suboptimal (40). In a Korean study, seven days course of levofloxacin, azithromycin and omeprazole have not been demonstrated to be more effective than seven days standard triple therapy (41).…”

Section: Discussionmentioning

confidence: 99%

Azithromycin based triple therapy versus standard clarithromycin based triple therapy in eradication of Helicobacter pylori infection in Iran: a randomized controlled clinical trial

Sarkeshikian¹,

Iranikhah²,

Ghadir³

2009

Turk J Gastroenterol

View full text Add to dashboard Cite

clarithromycin, amoxicillin, and omeprazole and azithromycin, amoxicillin, and omeprazole, respectively, and completed the study course. Per protocol, eradication rate was 83% with clarithromycin, amoxicillin, and omeprazole and 75% with azithromycin, amoxicillin, and omeprazole (p =0.158). Eradication rate for a subgroup of patients with peptic ulcer disease in two groups were 83% and 74%, respectively (p=0.134

show abstract

Pantoprazole, amoxycillin and either azithromycin or clarithromycin for eradication of Helicobacter pylori in duodenal ulcer

Abstract: Our study shows that 1-week triple therapy with pantoprazole, amoxycillin and either azithromycin or clarithromycin is not satisfactory (<80% ITT H. pylori eradication rate).

Cited by 17 publications

References 14 publications

Comparison of Azithromycin and Clarithromycin Triple Therapy Regimens for Helicobacter Pylori Eradication in hemodialysis Patients

Comparison of Azithromycin and Clarithromycin Triple Therapy Regimens for Helicobacter Pylori Eradication in hemodialysis Patients

Helicobacter pylori Current Chemotherapy and New Targets for Drug Design

Azithromycin based triple therapy versus standard clarithromycin based triple therapy in eradication of Helicobacter pylori infection in Iran: a randomized controlled clinical trial

Contact Info

Product

Resources

About